Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Recently Added/Updated trials
Validating a causal model of implementation for CBT
The goal of this study is to better understand how therapists make decisions about the treatment they deliver to clients.
We will test a causal model of implementation processes in the Philadelphia public mental health system. Our sample will be 200 clinicians and 400 clients across ~30 organizations who will complete measures of organizational and psychological variables after being trained in CBT. We will measure use of CBT via direct observation at two time points. A subset of clinicians will be recruited to complete follow-up interviews to explore moderators of the association between intentions.
Procedures include the child’s therapist will audio-record the child’s therapy session.
Dynamic Nuclear Polarization-MR Spectroscopic Imaging of Hepatocellular Carcinoma Metabolism to Predict Response Following Locoregional or Systemic Therapy
Phase 2
The research study is being conducted to evaluate a new imaging technique for detecting the response of hepatocellular carcinoma (HCC) to locoregional or systemic therapy. Locoregional therapies or LRT are called Transarterial Chemoembolization or TACE, Transarterial Radioembolization or TARE and Microwave Ablation or MWA. Systemic therapies or ST are therapy drugs that spread throughout the body to treat cancer cells. They include chemotherapy, hormonal therapy, targeted drugs, and immunotherapy.
Effects of the Contraceptive Implant in Women with Sickle Cell Disease (SCD CURE)
This research is being done to see if women who have sickle cell disease (SCD) experience any difference in their pain while using a hormonal implant as compared to when not using a hormonal implant (Nexplanon).
We are seeking women between the ages of 18 and 45 who have been diagnosed with SCD and have had at least 3 vaso-occlusive pain episodes in the previous 6 months. If you agree to join the study, you will be asked to complete the following research procedures: you will complete a 3-month “baseline” with no use of hormonal contraception (such as the birth control pill, ring, or injection), and then will have a contraceptive implant (Nexplanon) placed for 6 months. Your participation will last for a total of 9 months, with 3 in-person visits with a urine pregnancy test, blood draw, and surveys, as well as the completion of a daily text message questionnaire.
MVT-601A-006 MOXIE
The primary objective of this study is to characterize changes in bone mineral density (BMD) during continuous treatment with relugolix combination tablet (relugolix 40 mg/estradiol [E2] 1 mg/norethindrone acetate [NETA] 0.5 mg) for up to 48 months (4 years) in two cohorts: (1) premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and (2) premenopausal women with moderate to severe pain associated with endometriosis.
HPTN 102/PURPOSE 3
Phase 2
This is a Phase 2, open-label, multicenter, randomized study to evaluate the
PK, safety, and acceptability of LEN subcutaneous (SC) injection compared with oral F/TDF in cisgender women who would benefit from PrEP. This study has 2 parts. Randomized Phase: ppts will be randomized in a 1:1 ratio to receive 52 wks of LEN or F/TDF, followed by up to 78 wks of F/TDF for both study drug groups in the PK Tail Phase. Participants in the LEN group will transition to F/TDF for the PK Tail Phase.
CureTalks@Penn interviews Penn Medicine physicians about their cutting edge research and clinical trials. Our goal is to inform patients, care-givers, patient advocates and other physicians about research that occurs at Penn Medicine.
